: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription

Articles published in Ann Oncol
Retrieve available abstracts of 330 articles:
HTML format

Single Articles

May 2021

BLACKHALL FH
Reframing recalcitrance for small cell lung cancer.
Ann Oncol. 2021 May 3. pii: S0923-7534(21)01186.
PubMed

LACH KD, Sorin M, Huynh C, Alirezaie NS, et al
Combined small-cell lung carcinoma revealed to be an intratumoural metastasis by genetic analysis.
Ann Oncol. 2021;32:679-681.
PubMed

April 2021

DINGEMANS AC, Fruh M, Ardizzoni A, Besse B, et al
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger).
Ann Oncol. 2021 Apr 9. pii: S0923-7534(21)01113.
PubMed

SHI Y, Wu L, Yu X, Xing P, et al
Retraction notice to "30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)": [Annals of Oncology Volume 31, Supplement 7, Decemb
Ann Oncol. 2021;32:576.
PubMed Abstract available

BAUDIN E, Caplin M, Garcia-Carbonero R, Fazio N, et al
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up().
Ann Oncol. 2021;32:439-451.
PubMed

March 2021

STINCHCOMBE TE
EDITORIAL Lorlatinib in the treatment of anaplastic lymphoma kinase positive non-small-cell lung cancer.
Ann Oncol. 2021 Mar 16. pii: S0923-7534(21)00876.
PubMed

REMON J, Aldea M, Besse B, Planchard D, et al
Small cell lung cancer: a slightly less orphan disease after immunotherapy.
Ann Oncol. 2021 Mar 15. pii: S0923-7534(21)00877.
PubMed Abstract available

SZNOL M, Melero I
Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy.
Ann Oncol. 2021;32:295-297.
PubMed

February 2021

FELIP E, Shaw AT, Bearz A, Camidge DR, et al
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
Ann Oncol. 2021 Feb 24. pii: S0923-7534(21)00129.
PubMed Abstract available

SUBBIAH V, Shen T, Tetzlaff M, Weissferdt A, et al
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
Ann Oncol. 2021 Feb 19. pii: S0923-7534(21)00127.
PubMed

SPIGEL DR, Vicente D, Ciuleanu TE, Gettinger S, et al
Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.
Ann Oncol. 2021 Feb 1. pii: S0923-7534(21)00099.
PubMed Abstract available

SUBBIAH V, Shen T, Terzyan SS, Liu X, et al
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Ann Oncol. 2021;32:261-268.
PubMed Abstract available

SATURNO G, Lopes F, Niculescu-Duvaz I, Niculescu-Duvaz D, et al
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
Ann Oncol. 2021;32:269-278.
PubMed Abstract available

January 2021

CARIOLI G, Malvezzi M, Bertuccio P, Boffetta P, et al
European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer.
Ann Oncol. 2021 Jan 21. pii: S0923-7534(21)00014.
PubMed Abstract available

HILTBRUNNER S, Britschgi C, Schuberth P, Bankel L, et al
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial.
Ann Oncol. 2021;32:120-121.
PubMed

December 2020

PERETS R, Bar J, Rasco DW, Ahn MJ, et al
Safety and Efficacy of Quavonlimab, a Novel Anti-CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non-Small Cell Lung Cancer.
Ann Oncol. 2020 Dec 1. pii: S0923-7534(20)43175.
PubMed Abstract available

SHAVERDIAN N, Beattie J, Thor M, Offin M, et al
Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors.
Ann Oncol. 2020;31:1719-1724.
PubMed Abstract available

POPAT S, Curioni-Fontecedro A, Dafni U, Shah R, et al
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Ann Oncol. 2020;31:1734-1745.
PubMed Abstract available

LASKIN J, Liu SV, Tolba K, Heining C, et al
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
Ann Oncol. 2020;31:1693-1703.
PubMed Abstract available

MARINELLI D, Mazzotta M, Scalera S, Terrenato I, et al
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Ann Oncol. 2020;31:1746-1754.
PubMed Abstract available

SHI Y, Wu L, Yu X, Xing P, et al
RETRACTED: ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC).
Ann Oncol. 2020;31 Suppl 7:S1428.
PubMed Abstract available

November 2020

JEE J, Li BT
Expanding the nanotherapeutic toolbox for non-small-cell lung cancer.
Ann Oncol. 2020 Nov 22. pii: S0923-7534(20)43165.
PubMed

PAPADIMITRAKOPOULOU VA, Mok TS, Han JY, Ahn MJ, et al
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Ann Oncol. 2020;31:1536-1544.
PubMed Abstract available

MOSELE F, Remon J, Mateo J, Westphalen CB, et al
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
Ann Oncol. 2020;31:1491-1505.
PubMed Abstract available

BECKER T, Weberpals J, Jegg AM, So WV, et al
An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort.
Ann Oncol. 2020;31:1561-1568.
PubMed Abstract available

October 2020

SHI M, Gu A, Tu H, Huang C, et al
Comparing Nanoparticle Polymeric Micellar Paclitaxel and Solvent-based Paclitaxel as First-line Treatment of Advanced Non-Small Cell Lung Cancer: An Open-label, Randomized, Multicenter, Phase III Trial.
Ann Oncol. 2020 Oct 29. pii: S0923-7534(20)42982.
PubMed Abstract available

TAN L, Solomon BJ
Defining Resistance Mechanisms to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer (editorial re: Lin et al.).
Ann Oncol. 2020 Oct 9. pii: S0923-7534(20)42493.
PubMed

September 2020

LIN JJ, Liu SV, McCoach CE, Zhu VW, et al
Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer.
Ann Oncol. 2020 Sep 29. pii: S0923-7534(20)42465.
PubMed Abstract available

VAN DE GARDE EMW, van Bedaf LR, Hurkmans DP, van den Heuvel MM, et al
Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?
Ann Oncol. 2020 Sep 22. pii: S0923-7534(20)42457.
PubMed

PARK S, Ahn MJ
Osimertinib in CNS progressive EGFR-mutant lung cancer: Do we need to detect T790M?
Ann Oncol. 2020 Sep 2. pii: S0923-7534(20)42316.
PubMed

August 2020

FACCHINETTI F, Leonetti A, Tiseo M
Osimertinib in CNS-progressive EGFR-mutant lung cancer: Do we need to detect T790M?
Ann Oncol. 2020 Aug 13. pii: S0923-7534(20)42060.
PubMed

July 2020

PARK S, Lee MH, Seong M, Kim ST, et al
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Ann Oncol. 2020 Jul 4. pii: S0923-7534(20)39927.
PubMed Abstract available

June 2020

LUO J, Rizvi H, Preeshagul IR, Egger JV, et al
COVID-19 in patients with lung cancer.
Ann Oncol. 2020 Jun 16. pii: S0923-7534(20)39894.
PubMed Abstract available

PENTHEROUDAKIS G
Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC).
Ann Oncol. 2020 Jun 2. pii: S0923-7534(20)39865.
PubMed

QU J, Yang R, Song L, Kamel IR, et al
Atypical lung feature on chest CT in a lung adenocarcinoma cancer patient infected with COVID-19.
Ann Oncol. 2020;31:825-826.
PubMed

May 2020

MOK T, Camidge DR, Gadgeel SM, Rosell R, et al
TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Ann Oncol. 2020 May 11. pii: S0923-7534(20)39796.
PubMed Abstract available

CARIOLI G, Bertuccio P, Boffetta P, Levi F, et al
European cancer mortality predictions for the year 2020 with a focus on prostate cancer.
Ann Oncol. 2020;31:650-658.
PubMed Abstract available

SCHOENFELD AJ, Rizvi H, Bandlamudi C, Sauter JL, et al
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
Ann Oncol. 2020;31:599-608.
PubMed Abstract available

April 2020

SHIM JH, Kim HS, Cha H, Kim S, et al
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Ann Oncol. 2020 Apr 19. pii: S0923-7534(20)39295.
PubMed Abstract available

PASSARO A, Peters S, Mok TSK, Attili I, et al
Testing for COVID-19 in lung cancer patients.
Ann Oncol. 2020 Apr 9. pii: S0923-7534(20)39293.
PubMed

LIN G, Li C, Li PS, Fang WZ, et al
Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.
Ann Oncol. 2020;31:517-524.
PubMed Abstract available

HE Q, Shi X, Zhu H, Yan J, et al
A case treated with Crizotinib after secondary MET amplification of A double Rare L747S and G719S EGFR mutation Pulmonary Sarcomatoid Carcinoma.
Ann Oncol. 2020;31:544-546.
PubMed

PANJE CM, Lupatsch JE, Barbier M, Pardo E, et al
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland.
Ann Oncol. 2020;31:501-506.
PubMed Abstract available

METAXAS Y, Fruh M, Eboulet EI, Grosso F, et al
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Ann Oncol. 2020;31:495-500.
PubMed Abstract available

March 2020

SCHULER M, Berardi R, Lim WT, de Jonge M, et al
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a Phase I trial.
Ann Oncol. 2020 Mar 30. pii: S0923-7534(20)36380.
PubMed Abstract available

PAZ-ARES L, Spira A, Raben D, Planchard D, et al
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial.
Ann Oncol. 2020 Mar 21. pii: S0923-7534(20)36374.
PubMed Abstract available

LAMBERTI G, Spurr LF, Li Y, Ricciuti B, et al
Clinicopathological and genomic correlates of Programmed Cell Death Ligand 1 (PD-L1) expression in nonsquamous non-small cell lung cancer.
Ann Oncol. 2020 Mar 11. pii: S0923-7534(20)36078.
PubMed Abstract available

GAINOR JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, et al
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression >/=50.
Ann Oncol. 2020;31:404-411.
PubMed Abstract available

MAZZOTTA M, Filetti M, Rossi A, Roberto M, et al
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification.
Ann Oncol. 2020;31:440-441.
PubMed

February 2020

PLANCHARD D, Reinmuth N, Orlov S, Fischer JR, et al
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36041.
PubMed Abstract available

MANSFIELD AS, Kazarnowicz A, Karaseva N, Sanchez A, et al
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.
Ann Oncol. 2020;31:310-317.
PubMed Abstract available

MAZIERES J, Cropet C, Montane L, Barlesi F, et al
Vemurafenib in non-small-cell lung cancer patients with BRAF(V600) and BRAF(nonV600) mutations.
Ann Oncol. 2020;31:289-294.
PubMed Abstract available

PROS E, Saigi M, Alameda D, Gomez-Mariano G, et al
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
Ann Oncol. 2020;31:274-282.
PubMed Abstract available

PARK K, Vansteenkiste J, Lee KH, Pentheroudakis G, et al
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
Ann Oncol. 2020;31:191-201.
PubMed Abstract available

ZHAI H, Moore D, Jamal-Hanjani M
Inactivation of RB1 and histological transformation in EGFR-mutant lung adenocarcinoma.
Ann Oncol. 2020;31:169-170.
PubMed

ZHAO X, Shen J, Ivaturi V, Gopalakrishnan M, et al
Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.
Ann Oncol. 2020;31:302-309.
PubMed Abstract available

January 2020

OXNARD GR, Yang JC, Yu H, Kim SW, et al
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Ann Oncol. 2020 Jan 24. pii: S0923-7534(20)35946.
PubMed Abstract available

CHALABI M, Cardona A, Nagarkar DR, Dhawahir Scala A, et al
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
Ann Oncol. 2020 Jan 16. pii: S0923-7534(20)35927.
PubMed Abstract available

HAZELL SZ, Fu W, Hu C, Voong KR, et al
Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life.
Ann Oncol. 2020;31:96-102.
PubMed Abstract available

DE RUYSSCHER D, Faivre-Finn C, Nackaerts K, Jordan K, et al
Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer.
Ann Oncol. 2020;31:41-49.
PubMed Abstract available

December 2019

YOSHIOKA H, Shimokawa M, Seto T, Morita S, et al
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell
Ann Oncol. 2019;30:1978-1984.
PubMed Abstract available

KIM C, Liu SV
First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward.
Ann Oncol. 2019;30:1852-1855.
PubMed

November 2019

MOUNTZIOS G, Remon J, Novello S, Blais N, et al
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >/=1% by the USA Food and Drug Administration.
Ann Oncol. 2019;30:1686-1688.
PubMed

October 2019

KIM C, Liu SV
First-line EGFR TKI therapy in Non-Small Cell Lung Cancer: Looking back before leaping forward.
Ann Oncol. 2019 Oct 15. pii: 5587761. doi: 10.1093.
PubMed

DE VRIES R, Muller M, van der Noort V, Theelen WSME, et al
Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.
Ann Oncol. 2019;30:1660-1666.
PubMed Abstract available

AGUILAR EJ, Ricciuti B, Gainor JF, Kehl KL, et al
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
Ann Oncol. 2019;30:1653-1659.
PubMed Abstract available

September 2019

YOSHIOKA H, Shimokawa M, Seto T, Morita S, et al
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell
Ann Oncol. 2019 Sep 25. pii: 5573754. doi: 10.1093.
PubMed Abstract available

MOUNTZIOS G, Remon J, Novello S, Blais N, et al
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of >/= 1% by the U.S. Food and Drug Administration.
Ann Oncol. 2019 Sep 3. pii: 5559466. doi: 10.1093.
PubMed

KUDO Y, Haymaker C, Zhang J, Reuben A, et al
Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.
Ann Oncol. 2019;30:1521-1530.
PubMed Abstract available

August 2019

WEISS JM, Csoszi T, Maglakelidze M, Hoyer RJ, et al
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial.
Ann Oncol. 2019 Aug 27. pii: 5555303. doi: 10.1093.
PubMed Abstract available

AGUILAR EJ, Ricciuti B, Gainor JF, Kehl KL, et al
Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression.
Ann Oncol. 2019 Aug 21. pii: 5552557. doi: 10.1093.
PubMed Abstract available

July 2019

KUDO Y, Haymaker C, Zhang J, Reuben A, et al
Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer.
Ann Oncol. 2019 Jul 8. pii: 5529670. doi: 10.1093.
PubMed Abstract available

CHAMPIAT S, Besse B, Marabelle A
Hyperprogression during immunotherapy: do we really want to know?
Ann Oncol. 2019;30:1028-1031.
PubMed

TAMMINGA M, Groen HJM
Circulating tumor cells are prognostic in SCLC, but still lack clinical application.
Ann Oncol. 2019;30:1031-1033.
PubMed

PASTORINO U, Silva M, Sestini S, Sabia F, et al
Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy.
Ann Oncol. 2019;30:1162-1169.
PubMed Abstract available

KELLY RJ, Shepherd FA, Krivoshik A, Jie F, et al
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
Ann Oncol. 2019;30:1127-1133.
PubMed Abstract available

SHAW AT, Riely GJ, Bang YJ, Kim DW, et al
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
Ann Oncol. 2019;30:1121-1126.
PubMed Abstract available

TAY RY, Fernandez-Gutierrez F, Foy V, Burns K, et al
Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
Ann Oncol. 2019;30:1114-1120.
PubMed Abstract available

KIM CG, Kim KH, Pyo KH, Xin CF, et al
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
Ann Oncol. 2019;30:1104-1113.
PubMed Abstract available

ROTA M, Pizzato M, La Vecchia C, Boffetta P, et al
Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis.
Ann Oncol. 2019;30:1040-1043.
PubMed

June 2019

FRUH M, Peters S
EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in Non-Small Cell Lung Cancer.
Ann Oncol. 2019 Jun 14. pii: 5518918. doi: 10.1093.
PubMed

MAZIERES J, Drilon A, Lusque A, Mhanna L, et al
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Ann Oncol. 2019 May 24. pii: 5498206. doi: 10.1093.
PubMed Abstract available

HASTINGS K, Yu H, Wei W, Sanchez-Vega F, et al
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer.
Ann Oncol. 2019 May 14. pii: 5488949. doi: 10.1093.
PubMed Abstract available

KELLY RJ, Shepherd FA, Krivoshik A, Jie F, et al
A Phase 3, Randomized, Open-label Study of ASP8273 Versus Erlotinib or Gefitinib in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer.
Ann Oncol. 2019 May 9. pii: 5487410. doi: 10.1093.
PubMed Abstract available

PLANCHARD D, Popat S, Kerr K, Novello S, et al
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".
Ann Oncol. 2019;30:863-870.
PubMed

RICORDEL C, Friboulet L, Facchinetti F, Soria JC, et al
Correction to: "Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer".
Ann Oncol. 2019;30:858.
PubMed

BLUMENTHAL GM, Gong Y, Kehl K, Mishra-Kalyani P, et al
Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.
Ann Oncol. 2019;30:830-838.
PubMed Abstract available

April 2019

TAY RY, Fernandez-Gutierrez F, Foy V, Burns K, et al
Prognostic value of circulating tumour cells in limited-stage small cell lung cancer: analysis of the concurrent ONce-daily versus twice-daily RadioTherapy (CONVERT) randomised controlled trial.
Ann Oncol. 2019 Apr 24. pii: 5479461. doi: 10.1093.
PubMed Abstract available

KIM CG, Kim KH, Pyo KH, Xin CF, et al
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
Ann Oncol. 2019 Apr 12. pii: 5448854. doi: 10.1093.
PubMed Abstract available

PASTORINO U, Silva M, Sestini S, Sabia F, et al
Prolonged Lung Cancer Screening Reduced 10-year Mortality in the MILD Trial.
Ann Oncol. 2019 Apr 1. pii: 5425325. doi: 10.1093.
PubMed Abstract available

WIESWEG M, Mairinger F, Reis H, Goetz M, et al
Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer.
Ann Oncol. 2019;30:655-657.
PubMed

BONANNO L, Zulato E, Attili I, Pavan A, et al
Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy.
Ann Oncol. 2019;30 Suppl 2:ii9.
PubMed

JUAN VIDAL OJ, Simarro J, Lorente Estelles D, Perez-Simo G, et al
Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1(st) or 2(nd) generation EGFR tyrosine kinase inhibitors (TKIs).
Ann Oncol. 2019;30 Suppl 2:ii9-ii10.
PubMed

OWONIKOKO TK, Kim HR, Govindan R, Ready N, et al
Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, r
Ann Oncol. 2019;30 Suppl 2:ii77.
PubMed

THOTTIAN AGF, Babu GK, Dasappa L, Jacob LA, et al
Evaluation of safety and efficacy of minocycline combined with tyrosine kinase inhibitors in patients of EGFR mutated metastatic lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii76.
PubMed

BUNTZEL J, Heinz J, Rover C, Bleckmann A, et al
Sarcopenia as prognostic factor in lung cancer patients: A systematic review and meta-analysis.
Ann Oncol. 2019;30 Suppl 2:ii76.
PubMed

KIRITA K, Udagawa H, Matsumoto S, Yoh K, et al
Feasibility and utility of transbronchial cryobiopsy in primary lung cancer: Prospective, single arm study.
Ann Oncol. 2019;30 Suppl 2:ii76.
PubMed

LEE SC, Kwak S, Park MS, Kim YS, et al
Diagnostic value of concomitant use of radial probe endobronchial ultrasound with guide sheath and transbronchial biopsy in lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii75.
PubMed

CIPRIANO E, Tavares A, Soares A, Estevinho F, et al
Non-small cell lung cancer in the elderly: A retrospective study comparing first-line treatment with single-agent vs combination chemotherapy vs tyrosine kinase inhibitor.
Ann Oncol. 2019;30 Suppl 2:ii75.
PubMed

TSIOUPROU I, Tsartsianidou V, Papaemmanouil S, Pastelli N, et al
Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center.
Ann Oncol. 2019;30 Suppl 2:ii75.
PubMed

NAISH P, Purdy E
Information for lung cancer patients and their caregivers: A systematic analysis of the online landscape.
Ann Oncol. 2019;30 Suppl 2:ii74.
PubMed

GODARA SK, Beniwal SK
Psychosocial and financial impact on family of lung cancer patients: A cancer research center experience.
Ann Oncol. 2019;30 Suppl 2:ii74.
PubMed

LEVENTAKOS K, Helgeson J, Mansfield AS, Deering E, et al
Implementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center.
Ann Oncol. 2019;30 Suppl 2:ii74.
PubMed

MEHTA M, Gondi V, Ahluwalia M, Brown P, et al
Phase III METIS study: Tumor treating fields (150 kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC).
Ann Oncol. 2019;30 Suppl 2:ii70-ii71.
PubMed

LINDSAY CR, Blackhall FH, Carmel A, Gazzaniga P, et al
EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii7.
PubMed

DUMOULIN D, de Goeje P, Poncin M, Bezemer K, et al
Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors.
Ann Oncol. 2019;30 Suppl 2:ii7.
PubMed

FERRARA R, Naigeon M, Auclin E, Duchemann B, et al
Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts).
Ann Oncol. 2019;30 Suppl 2:ii7-ii8.
PubMed

RANISZEWSKA A, Rutkowska E, Sokolowski R, Domagala-Kulawik J, et al
Characterization and potential role of PD-L1 positive lung cancer stem cells in lymph nodes metastasis.
Ann Oncol. 2019;30 Suppl 2:ii69.
PubMed

GELSOMINO F, Tiseo M, Boni L, Cavanna L, et al
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial.
Ann Oncol. 2019;30 Suppl 2:ii67-ii68.
PubMed

PAZ-ARES L, Senan S, Planchard D, Wang L, et al
RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC).
Ann Oncol. 2019;30 Suppl 2:ii67.
PubMed

PAIK P, Cortot A, Felip E, Sakai H, et al
A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study.
Ann Oncol. 2019;30 Suppl 2:ii66.
PubMed

SHIMOKAWA M, Nosaki K, Seto T, Ohashi K, et al
Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.
Ann Oncol. 2019;30 Suppl 2:ii66.
PubMed

PLANCHARD D, Li BT, Murakami H, Shiga R, et al
A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii66-ii67.
PubMed

SPICER J, Provencio M, Garrido Lopez P, Bosch-Barrera J, et al
An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii65-ii66.
PubMed

FRUEH M, Rahma OE, Pachynski RK, Mazieres J, et al
Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice.
Ann Oncol. 2019;30 Suppl 2:ii65.
PubMed

ABDULLA DS, Ruge M, Scheffler M, Nogova L, et al
Feasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for treatment monitoring of brain metastases in lung cancer patients.
Ann Oncol. 2019;30 Suppl 2:ii64-ii65.
PubMed

ALTINI M, Massa I, Balzi W, Gentili N, et al
Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy.
Ann Oncol. 2019;30 Suppl 2:ii63-ii64.
PubMed

MARTINEZ KAREAGA M, Urbieta-Macazaga N, Sanchez-Vieco C, Tomas-Lopez L, et al
Permanent pleural catheter (PPC) for malignant pleural effusion (PE) in advanced non-small cell lung cancer (NSCLC).
Ann Oncol. 2019;30 Suppl 2:ii63.
PubMed

HAN B, Li K, Chu T, Bi M, et al
A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung c
Ann Oncol. 2019;30 Suppl 2:ii62.
PubMed

NIE W, Xu MD, Gan L, Zhang Y, et al
Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade.
Ann Oncol. 2019;30 Suppl 2:ii62.
PubMed

RAPOPORT BL, Vorobiof DA, Langenhoven L, Hall JM, et al
Prognostic significance of neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii61.
PubMed

ROUNIS K, Papadaki C, Makrakis D, Monastirioti A, et al
Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a prospective, observational, single institut
Ann Oncol. 2019;30 Suppl 2:ii61.
PubMed

CORRAL DE LA FUENTE E, Barquin Garcia A, Saavedra Serrano C, Olmedo Garcia ME, et al
Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP).
Ann Oncol. 2019;30 Suppl 2:ii61-ii62.
PubMed

DI NOIA V, D'Argento E, Vita E, Ferrara M, et al
Monitoring of blood serum amyloid (SAA) to predict outcome of first-line pembrolizumab (P) in patients (pts) with advanced non-small cell lung cancer (ANSCLC).
Ann Oncol. 2019;30 Suppl 2:ii60.
PubMed

FAEHLING M, Schwenk B, Kopp M, Fallscheer S, et al
Immuno-oncological treatment and tumor load in non-small cell lung cancer (NSCLC): Case-control analysis of overall survival (OS) in routine clinical practice.
Ann Oncol. 2019;30 Suppl 2:ii60.
PubMed

LANDRE T, Des Guetz G, Vergnenegre A, Chouaid C, et al
Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis.
Ann Oncol. 2019;30 Suppl 2:ii60.
PubMed

JERMANN P, Alborelli I, Leonards K, Rothschild SI, et al
Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii59.
PubMed

PRELAJ A, Lo Russo G, Signorelli D, Ferrara R, et al
EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy.
Ann Oncol. 2019;30 Suppl 2:ii59.
PubMed

PRELAJ A, Rebuzzi SE, Pizzutilo P, Bilancia M, et al
Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients.
Ann Oncol. 2019;30 Suppl 2:ii58.
PubMed

PAVAN A, Calvetti L, Dal Maso A, Attili I, et al
Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse.
Ann Oncol. 2019;30 Suppl 2:ii58-ii59.
PubMed

SCHETT A, Rothschild SI, Mauti LA, Schmid S, et al
Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies.
Ann Oncol. 2019;30 Suppl 2:ii58.
PubMed

SAAVEDRA SERRANO C, Barquin Garcia A, Corral de la Fuente E, Serrano Domingo JJ, et al
Association of immune-related adverse events (irAEs) and immunotherapy (IT) benefit in advanced non-small cell lung cancer (NSCLC).
Ann Oncol. 2019;30 Suppl 2:ii57-ii58.
PubMed

HORINOUCHI H, Nogami N, Saka H, Nishio M, et al
Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study.
Ann Oncol. 2019;30 Suppl 2:ii56-ii57.
PubMed

GALLI G, Proto C, Signorelli D, Imbimbo M, et al
Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy.
Ann Oncol. 2019;30 Suppl 2:ii56.
PubMed

SCHEFFLER M, Frank R, Ihle MA, Abdulla DS, et al
Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 comutations in non-small cell lung cancer (NSCLC).
Ann Oncol. 2019;30 Suppl 2:ii55.
PubMed

KHO CYX, Lim DW, Tan DSW, Tan WL, et al
Clinicopathological characteristics and outcome of advanced ROS1-positive non-small cell lung cancer in Asian patients.
Ann Oncol. 2019;30 Suppl 2:ii54.
PubMed

PASSARO A, Prelaj A, Spitaleri G, Del Signore E, et al
Clinical and treatment features associated with improved 5-year survival rate in ALK-positive lung cancer treated with ALK-TKIs.
Ann Oncol. 2019;30 Suppl 2:ii54.
PubMed

ZHAO Y, Zhang B, Zhang Y, Wang S, et al
Role of radiotherapy in management of brain metastases in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A single-center retrospective study.
Ann Oncol. 2019;30 Suppl 2:ii54.
PubMed

ANGELATS L, Garcia Campelo MR, Bernabe Caro R, Arriola Aperribay E, et al
Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p).
Ann Oncol. 2019;30 Suppl 2:ii53.
PubMed

PAN X, Lin MM, Yin Y, Hou P, et al
Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States.
Ann Oncol. 2019;30 Suppl 2:ii52-ii53.
PubMed

ZHANG Y, Liu T, Zeng Y, Zhu J, et al
PD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small cell lung cancer via inducing EMT phenotype.
Ann Oncol. 2019;30 Suppl 2:ii52.
PubMed

KRPINA K, Budimir B, Kukulj S, Marusic A, et al
Correlation of molecular status and anatomic sites of metastases at diagnosis of EGFR positive non-small cell lung cancer (NSCLC): A single institution experience.
Ann Oncol. 2019;30 Suppl 2:ii52.
PubMed

FASSUNKE J, Heydt C, Michels S, Van Veggel B, et al
New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii51.
PubMed

SOW ML, El Yacoubi H, Moukafih B, Balde S, et al
Frequency and types of EGFR mutation in Moroccan patients with non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii50.
PubMed

ZHANG J, Zhou ZS, Su YC, Yu TQ, et al
Relationship of clinicopathological characteristics, EGFR genotyping and prognosis in non-small cell lung cancer patients with malignant pleural effusion.
Ann Oncol. 2019;30 Suppl 2:ii50.
PubMed

LIAN Z, Du W, Zhu J, Zeng Y, et al
Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii50.
PubMed

JIA H, Qi H, Peng J, Li M, et al
FOXP3Delta3, the major isoform of FOXP3, promotes proliferation, migration, and invasion in non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii5-ii6.
PubMed

ZHU Y, Xu C, Wang W, Zhang Q, et al
The characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis.
Ann Oncol. 2019;30 Suppl 2:ii5.
PubMed

KOKKOTOU E, Rapti V, Grapsa D, Bakakos P, et al
Immunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features.
Ann Oncol. 2019;30 Suppl 2:ii5.
PubMed

CORDOBA ORTEGA JF, Salud A, Morales S, Veas J, et al
TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor.
Ann Oncol. 2019;30 Suppl 2:ii5.
PubMed

LI J, Nickens DJ, Wilner K, Tan W, et al
The effect of proton pump inhibitors (PPI) on dacomitinib (DACO) pharmacokinetics and efficacy in non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutation.
Ann Oncol. 2019;30 Suppl 2:ii49.
PubMed

SHARMA D, Slevin F, Clarke K, Franks K, et al
Regional retrospective analysis of outcomes of EGFR mutated non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire.
Ann Oncol. 2019;30 Suppl 2:ii49.
PubMed

BARLESI F, Drilon A, De Braud F, Cho BC, et al
Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2.
Ann Oncol. 2019;30 Suppl 2:ii48-ii49.
PubMed

SRINIVASALU VK, Subramaniam N, Raghuram S, Kolathu S, et al
Thromboembolic events in advanced non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii48-ii49.
PubMed

SHAW A, Riely GJ, Bang YJ, Kim DW, et al
Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001.
Ann Oncol. 2019;30 Suppl 2:ii48-ii49.
PubMed

XU C, Wang W, Zhu Y, Yu Z, et al
Potential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study.
Ann Oncol. 2019;30 Suppl 2:ii48.
PubMed

DRILON A, Kummar S, Moreno V, Patel J, et al
Activity of larotrectinib in TRK fusion lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii48-ii49.
PubMed

PAZ-ARES L, Doebele RC, Farago AF, Liu SV, et al
Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001.
Ann Oncol. 2019;30 Suppl 2:ii48-ii49.
PubMed

ALDEA M, Hendriks L, Mezquita L, Remon-Masip J, et al
Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts).
Ann Oncol. 2019;30 Suppl 2:ii48.
PubMed

HORN L, Whisenant JG, Wakelee H, Reckamp KL, et al
Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).
Ann Oncol. 2019;30 Suppl 2:ii48.
PubMed

NIE W, Qian J, Han BH
Blood tumor mutational burden as a predictor of clinical benefit in non-small cell lung cancer patients treated with docetaxel: Secondary analysis of the OAK and POPLAR randomized clinical trials.
Ann Oncol. 2019;30 Suppl 2:ii48.
PubMed

PEROL M, Dixmier A, Barlesi F, Debieuvre D, et al
Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study.
Ann Oncol. 2019;30 Suppl 2:ii48.
PubMed

ROEPER J, Lueers AC, Falk M, Schatz S, et al
Risk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients.
Ann Oncol. 2019;30 Suppl 2:ii48.
PubMed

YANG JC, Ramalingam SS, Lee CK, Kurata T, et al
Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts.
Ann Oncol. 2019;30 Suppl 2:ii48.
PubMed

SHEMESH R, Gorzalczany Y, Sagi-Eisenberg R, Geva S, et al
The micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact.
Ann Oncol. 2019;30 Suppl 2:ii4.
PubMed

ZHANG Q, Xu C, Wang W, Zhuang W, et al
Clinicopathologic characteristics of patients with TP63 mutations in Chinese non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii4.
PubMed

LIANG L, Hui K, Hu C, Wen Y, et al
Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
Ann Oncol. 2019;30 Suppl 2:ii4.
PubMed

ROITBERG FSR, Neffa MFBV, Bonadio RRCC, Harada G, et al
Efficacy and safety of adjuvant chemotherapy in lung cancer: Real-world evidence.
Ann Oncol. 2019;30 Suppl 2:ii37.
PubMed

EZE C, Taugner J, Kasmann L, Roengvoraphoj O, et al
Pattern of first-site failure and salvage treatment in patients with inoperable stage III non-small cell lung cancer after chemoradiotherapy.
Ann Oncol. 2019;30 Suppl 2:ii36.
PubMed

TAUGNER J, Kasmann L, Eze C, Dantes M, et al
Heterogeneity score in inoperable stage III non-small cell lung cancer patients treated with definitive chemoradiotherapy: A single centre analysis.
Ann Oncol. 2019;30 Suppl 2:ii35.
PubMed

HARBEGUE K, Mejri N, El Benna H, Labidi S, et al
Challenges in the management of stage III non-small cell lung cancer (NSCLC) within multidisciplinary team (MDT): A lung cancer center experience.
Ann Oncol. 2019;30 Suppl 2:ii35.
PubMed

GIRARD N, Perol M, Simon G, Audigier Valette C, et al
Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database.
Ann Oncol. 2019;30 Suppl 2:ii34.
PubMed

GREEN A, Olsen KE, Bliddal M, Christensen HN, et al
Treatment patterns and long-term survival for unresected stage III non-small cell lung cancer patients: A nationwide register study in Denmark.
Ann Oncol. 2019;30 Suppl 2:ii34.
PubMed

PRELAJ A, Rebuzzi SE, Pizzutilo P, Bilancia M, et al
Time-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients.
Ann Oncol. 2019;30 Suppl 2:ii34.
PubMed

CREELAN BC, Yeh T, Kim SW, Nogami N, et al
Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations.
Ann Oncol. 2019;30 Suppl 2:ii31-ii32.
PubMed

PETERS S, Kim AW, Solomon B, Gandara DR, et al
IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy.
Ann Oncol. 2019;30 Suppl 2:ii30.
PubMed

ROCHA P, Rodrigo M, Moliner L, Hardy-Werbin M, et al
Higher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii30.
PubMed

CORDOBA ORTEGA JF, Salud A, Morales S, Veas J, et al
High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC).
Ann Oncol. 2019;30 Suppl 2:ii30.
PubMed

DROSSLEROVA M, Sterclova M, Vasakova M, Taskova A, et al
Role of chemokines in resectable non-small cell lung cancer (NSCLC).
Ann Oncol. 2019;30 Suppl 2:ii3.
PubMed

WANG W, Xu C, Zhang Q, Zhuang W, et al
The prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations.
Ann Oncol. 2019;30 Suppl 2:ii3-ii4.
PubMed

GE H, Chen X, Ruan L, Gao Q, et al
Clinical validation of an NGS-based assay for detecting multiple genomic alterations in Chinese patients with non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii3.
PubMed

PIROGOV SS, Telegina L, Sokolov V, Karmakova T, et al
Endobronchial surgery and photodynamic therapy for early central lung cancer treatment.
Ann Oncol. 2019;30 Suppl 2:ii29.
PubMed

GAGLIASSO M, Cartia CF, Maraschi A, Rapana R, et al
The prognostic impact of the international association for the study of lung cancer (IASLC) definitions on completeness of surgical resection for non-small cell lung cancer (NSCLC).
Ann Oncol. 2019;30 Suppl 2:ii29.
PubMed

CHEN X, Deng Y, Shi Y
Tissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii29.
PubMed

SUN F, Banfill K, Lilley J, Wheller B, et al
Multi-centre analysis of cardiac events following radical radiotherapy for lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii27.
PubMed

KIM H, Yoo H, Pyo H, Park HY, et al
Impact of underlying pulmonary diseases on treatment outcomes in early stage non-small cell lung cancer treated with definitive radiotherapy.
Ann Oncol. 2019;30 Suppl 2:ii27.
PubMed

SENAN S, Shire N, Mak G, Yao W, et al
ADRIATIC: A phase III trial of durvalumab +/- tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii25.
PubMed

JAT RR, Rai RK, Jakhar SL, Beniwal SK, et al
Experience of prophylactic cranial irradiation in extensive stage small cell lung cancer at a regional cancer center in India.
Ann Oncol. 2019;30 Suppl 2:ii24.
PubMed

SEBASTIAN M, Barlesi F, Califano R, Mansfield AS, et al
Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice.
Ann Oncol. 2019;30 Suppl 2:ii24.
PubMed

KASMANN L, Abdo R, Taugner J, Eze C, et al
External validation of a survival score for limited stage small cell lung cancer treated with chemoradiotherapy.
Ann Oncol. 2019;30 Suppl 2:ii23.
PubMed

MCSORLEY LM, Goggin CM, Elhadi N, O'Dea P, et al
Timing of treatment with concurrent chemoradiotherapy (CRT) and impact on progression free survival (PFS) in limited stage small cell lung cancer (LSSCLC).
Ann Oncol. 2019;30 Suppl 2:ii23-ii24.
PubMed

YU J, Ouyang W, Hu J, Zhang J, et al
Value of post-radiotherapy for limited stage small cell lung cancer on basis of a prognostic scoring model.
Ann Oncol. 2019;30 Suppl 2:ii23.
PubMed

LIU J, Zhou H, Zhang Y, Fang W, et al
Nomogram for patients with stage I small cell lung cancer: A competing risk analysis.
Ann Oncol. 2019;30 Suppl 2:ii22.
PubMed

BUSHRA S, Tibdewal A, Mummudi N, Kinhikar R, et al
Comparison of internal target volume delineation using CT datasets of four-dimensional computed tomography in lung cancer radiotherapy.
Ann Oncol. 2019;30 Suppl 2:ii21.
PubMed

GUNDU N, Malik PS, Khurana S, Pathy S, et al
Non-small cell lung carcinoma (NSCLC) patients with baseline brain imaging: A prospective observational study.
Ann Oncol. 2019;30 Suppl 2:ii20.
PubMed

SON C
Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii2.
PubMed

WEINBERG U, Kaynan N, Voloshin Sela T, Davidi S, et al
Immunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models.
Ann Oncol. 2019;30 Suppl 2:ii2-ii3.
PubMed

LEE KA, Felix W, Jackson G
Concordance, decision impact, and satisfaction for a computerized clinical decision support system in treatment of lung cancer patients.
Ann Oncol. 2019;30 Suppl 2:ii19.
PubMed

MCCANN K, Faisal W
Invasive diagnostic investigation-related complications and its impact on treatment initiation in lung cancer patients in a rapid access lung lesion clinic in regional Australia.
Ann Oncol. 2019;30 Suppl 2:ii19.
PubMed

AKTER MS, Ahmed S
Pulmonary tuberculosis: A hurdle to overcome for early lung cancer diagnosis in TB burden countries.
Ann Oncol. 2019;30 Suppl 2:ii19.
PubMed

LIU J, Zhou H, Zhang Y, Fang W, et al
A Mendelian randomization study of the effects of Crohn's disease on lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii18.
PubMed

ZHOU H, Zhang Y, Liu J, Yang Y, et al
Education and lung cancer: A Mendelian randomisation study.
Ann Oncol. 2019;30 Suppl 2:ii18.
PubMed

LELEU O, Auquier MA, Chauffert B, Berna P, et al
Baseline results from a French pilot study on lung cancer screening by CT scan: DEP KP80.
Ann Oncol. 2019;30 Suppl 2:ii14.
PubMed

KIM Y
Implementation of organized lung cancer screening program in Korea.
Ann Oncol. 2019;30 Suppl 2:ii14.
PubMed

KUO TC, Hsiao TH, Yang PC
The metabolic phenotypes of non-small cell lung cancer cells in association with clinical treatment strategies.
Ann Oncol. 2019;30 Suppl 2:ii13.
PubMed

LI CC, He Q, Liang H, He J, et al
Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of advanced lung cancer: A meta-analysis.
Ann Oncol. 2019;30 Suppl 2:ii13.
PubMed

LIANG L, Hu C, Wen Y, Zhuang W, et al
High dose apatinib in the reversal of immunosuppressive tumor microenvironment for irradiation therapy in lung carcinoma.
Ann Oncol. 2019;30 Suppl 2:ii12.
PubMed

DIMITRAKOPOULOS FD, Antonacopoulou A, Kottorou A, Tzelepi V, et al
Genetic variation of lymphotoxin beta receptor (LTbetaR) rs10849448 (A/G) is associated with risk for lung cancer and metastatic spread to adrenals.
Ann Oncol. 2019;30 Suppl 2:ii12.
PubMed

YEH YT, Wu CR, Lai JC, Huang CH, et al
Impacts of HDAC2 inhibition on lung cancer treatment.
Ann Oncol. 2019;30 Suppl 2:ii11.
PubMed

DOMAGALA-KULAWIK J, Skirecki T, Dziedzic D, Polubiec-Kownacka M, et al
Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii10.
PubMed

KOTSANTIS I, Economopoulou P, Psyrri A, Maratou E, et al
Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer.
Ann Oncol. 2019;30 Suppl 2:ii10.
PubMed

KUIJPERS C, Van den Heuvel M, Overbeek L, Van Lindert A, et al
Notable variation of molecular testing in metastatic lung cancer in the Netherlands.
Ann Oncol. 2019;30 Suppl 2:ii1-ii2.
PubMed

JANUSZEWSKI A, Zhang YZ, Chang WC, Laggner U, et al
Impact of MET variants on PD-L1 expression in pleomorphic lung carcinoma.
Ann Oncol. 2019;30 Suppl 2:ii1.
PubMed

March 2019

PETERS S, Reck M, Smit EF, Mok T, et al
How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.
Ann Oncol. 2019 Mar 26. pii: 5420157. doi: 10.1093.
PubMed Abstract available

HANNIGAN B, Ye W, Mehrotra M, Lam V, et al
Liquid Biopsy Assay for Lung Carcinoma Using Centrifuged Supernatants from Fine Needle Aspiration Specimens.
Ann Oncol. 2019 Mar 18. pii: 5384494. doi: 10.1093.
PubMed Abstract available

EKMAN S
HER2: defining a Neu target in non-small-cell lung cancer.
Ann Oncol. 2019;30:353-355.
PubMed

February 2019

BLUMENTHAL GM, Gong Y, Kehl K, Mishra-Kalyani P, et al
Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in clinical trials of patients with non-small cell lung cancer.
Ann Oncol. 2019 Feb 22. pii: 5362014. doi: 10.1093.
PubMed Abstract available

WIESWEG M, Mairinger F, Reis H, Goetz M, et al
Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small cell lung cancer.
Ann Oncol. 2019 Feb 11. pii: 5315508. doi: 10.1093.
PubMed

MORABITO A
Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is 'promoted'!
Ann Oncol. 2019 Feb 2. pii: 5306111. doi: 10.1093.
PubMed

AMARAL SR, Casal Moura M, Carvalho J, Chaves A, et al
6PPrognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors.
Ann Oncol. 2019;30.
PubMed

WANG M, Ma X
26PTexture analysis in contrast enhanced CT: New method to predict prognosis of small cell lung cancer treated with platinum-based chemotherapy.
Ann Oncol. 2019;30.
PubMed

XIE Y
35PEnhancement of high-LET radiation-induced lung cancer cell apoptosis by Antennapedia proteins (ANTP)-SmacN7.
Ann Oncol. 2019;30.
PubMed

BRONTE G, Puccetti M, Crino L, Bravaccini S, et al
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression.
Ann Oncol. 2019;30:339-340.
PubMed

BOFFETTA P, Righi L, Ciocan C, Pelucchi C, et al
Reply to letters to the editor by Brentisci et al. and Consonni and Mensi.
Ann Oncol. 2019;30:341.
PubMed

CONSONNI D, Mensi C
Comment on the paper 'Boffetta et al. Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy. Ann Oncol 2018; 29(2): 484-489'.
Ann Oncol. 2019;30:340-341.
PubMed

WU YL, Planchard D, Lu S, Sun H, et al
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.
Ann Oncol. 2019;30:171-210.
PubMed Abstract available

MORABITO A
Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is 'promoted'!
Ann Oncol. 2019;30:165-167.
PubMed

PETERS S, Dafni U, Boyer M, De Ruysscher D, et al
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Ann Oncol. 2019;30:161-165.
PubMed

AMARAL SR, Casal Moura M, Carvalho J, Chaves A, et al
Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors.
Ann Oncol. 2019;30 Suppl 1:i3.
PubMed

XIE Y
Enhancement of high-LET radiation-induced lung cancer cell apoptosis by Antennapedia proteins (ANTP)-SmacN7.
Ann Oncol. 2019;30 Suppl 1:i13.
PubMed

WANG M, Ma X
Texture analysis in contrast enhanced CT: New method to predict prognosis of small cell lung cancer treated with platinum-based chemotherapy.
Ann Oncol. 2019;30 Suppl 1:i10.
PubMed

January 2019

ZUO H, Ueland PM, Midttun O, Tell GS, et al
Vitamin B6 catabolism and lung cancer risk: results from the Lung Cancer Cohort Consortium (LC3).
Ann Oncol. 2019 Jan 30. pii: 5304407. doi: 10.1093.
PubMed Abstract available

PLANCHARD D, Popat S, Kerr K, Novello S, et al
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2019 Jan 30. pii: 5304567. doi: 10.1093.
PubMed

PETERS S, Dafni U, Boyer M, De Ruysscher D, et al
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Ann Oncol. 2019 Jan 8. pii: 5280724. doi: 10.1093.
PubMed

DE LIMA LOPES G, Aguiar P Jr
Reply to the letter to the editor 'Response to the effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors' by Ogale.
Ann Oncol. 2019;30:149-150.
PubMed

December 2018

WANG Y, Jiang T, Qin Z, Jiang J, et al
HER2 exon 20 insertions in Non-Small Cell Lung Cancer are Sensitive to the Irreversible Pan-HER Receptor Tyrosine Kinase Inhibitor Pyrotinib.
Ann Oncol. 2018 Dec 31. pii: 5267836. doi: 10.1093.
PubMed Abstract available

WU YL, Planchard D, Lu S, Sun H, et al
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer; a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.
Ann Oncol. 2018 Dec 28. pii: 5265324. doi: 10.1093.
PubMed Abstract available

October 2018

WAN Y, Liu B, Lei H, Zhang B, et al
Nanoscale Extracellular Vesicle-Derived DNA is Superior to Circulating Cell Free DNA for Mutation Detection in Early-Stage Non-Small Cell Lung Cancer.
Ann Oncol. 2018 Oct 18. pii: 5136413. doi: 10.1093.
PubMed Abstract available

GADGEEL S, Peters S, Mok T, Shaw AT, et al
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
Ann Oncol. 2018 Sep 12. pii: 5095692. doi: 10.1093.
PubMed Abstract available

TANIGUCHI Y, Takeda M, Tamiya A, Kasai T, et al
Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small cell lung cancer.
Ann Oncol. 2018 Sep 10. pii: 5094491. doi: 10.1093.
PubMed

August 2018

KRON A, Alidousty C, Scheffler M, Merkelbach-Bruse S, et al
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
Ann Oncol. 2018 Aug 23. pii: 5079835. doi: 10.1093.
PubMed Abstract available

COSTA DB
TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer.
Ann Oncol. 2018 Aug 23. pii: 5110095. doi: 10.1093.
PubMed

THOMAS M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, et al
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study.
Ann Oncol. 2018 Aug 20. pii: 5076437. doi: 10.1093.
PubMed Abstract available

July 2018

BASU B, Krebs MG, Sundar R, Wilson RH, et al
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.
Ann Oncol. 2018 Jul 17. pii: 5055047. doi: 10.1093.
PubMed Abstract available

SORIA JC, Ho SN, Varella-Garcia M, Iafrate AJ, et al
Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small cell lung cancer.
Ann Oncol. 2018 Jul 13. pii: 5053587. doi: 10.1093.
PubMed Abstract available

COTTRELL TR, Thompson ED, Forde PM, Stein JE, et al
Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Criteria (irPRC).
Ann Oncol. 2018 Jul 6. pii: 5049993. doi: 10.1093.
PubMed Abstract available

RICORDEL C, Friboulet L, Facchinetti F, Soria JC, et al
Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
Ann Oncol. 2018 Jul 3. pii: 5048419. doi: 10.1093.
PubMed

June 2018

BONOMI PD, Gandara D, Hirsch FR, Kerr KM, et al
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
Ann Oncol. 2018 Jun 14. pii: 5037893. doi: 10.1093.
PubMed Abstract available

May 2018

GERBER DE, Horn L, Boyer M, Sanborn R, et al
Randomized phase 3 study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.
Ann Oncol. 2018 May 14. pii: 4996069. doi: 10.1093.
PubMed Abstract available

April 2018

PINATO DJ, Kythreotou A, Mauri FA, Suardi E, et al
Functional immune characterization of HIV-associated non-small cell lung cancer.
Ann Oncol. 2018 Apr 20. pii: 4979448. doi: 10.1093.
PubMed

NOVELLO S, Mazieres J, Oh IJ, de Castro J, et al
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
Ann Oncol. 2018 Apr 14. pii: 4970555. doi: 10.1093.
PubMed Abstract available

WANG H, Agulnik J, Kasymjanova G, Wang A, et al
Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer.
Ann Oncol. 2018 Apr 12. pii: 4969231. doi: 10.1093.
PubMed Abstract available

MULLER DC, Hodge AM, Fanidi A, Albanes D, et al
No association between circulating concentrations of vitamin D and risk of lung cancer: An analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3).
Ann Oncol. 2018 Apr 2. pii: 4958387. doi: 10.1093.
PubMed Abstract available

DACIC S
Time is up for PD-L1 testing standardization in lung cancer.
Ann Oncol. 2018;29:791-792.
PubMed

March 2018

DEROSA L, Hellmann MD, Spaziano M, Halpenny D, et al
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small cell lung cancer.
Ann Oncol. 2018 Mar 30. pii: 4956695. doi: 10.1093.
PubMed Abstract available

TAO MH, Chen S, Freudenheim JL, Cauley JA, et al
Oral bisphosphonate use and lung cancer incidence among postmenopausal women.
Ann Oncol. 2018 Mar 29. pii: 4956655. doi: 10.1093.
PubMed Abstract available

February 2018

MCCOACH CE, Blumenthal GM, Zhang L, Myers A, et al
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.
Ann Oncol. 2018 Feb 26. pii: 4909805. doi: 10.1093.
PubMed

VOKES EE, Ready N, Felip E, Horn L, et al
Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Ann Oncol. 2018 Feb 2. pii: 4835443. doi: 10.1093.
PubMed Abstract available

January 2018

ADAM J, Le Stang N, Rouquette I, Cazes A, et al
Multicenter French harmonization study for PD-L1 IHC testing in non-small cell lung cancer.
Ann Oncol. 2018 Jan 16. pii: 4812668. doi: 10.1093.
PubMed Abstract available

LI YS, Jiang BY, Yang JJ, Zhang XC, et al
Unique Genetic Profiles from Cerebrospinal Fluid Cell-free DNA in Leptomeningeal Metastases of EGFR-mutant Non-Small Cell Lung Cancer: A New Medium of Liquid Biopsy.
Ann Oncol. 2018 Jan 15. pii: 4810473. doi: 10.1093.
PubMed Abstract available

LAVOLE A, Guihot A, Veyri M, Lambotte O, et al
PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?
Ann Oncol. 2018 Jan 15. pii: 4810471. doi: 10.1093.
PubMed

GUIBERT N, Hu Y, Feeney N, Kuang Y, et al
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
Ann Oncol. 2018 Jan 9. pii: 4794870. doi: 10.1093.
PubMed Abstract available

GHORANI E, Rosenthal R, McGranahan N, Reading JL, et al
Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.
Ann Oncol. 2018;29:271-279.
PubMed Abstract available

ILIE M, Szafer-Glusman E, Hofman V, Chamorey E, et al
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Ann Oncol. 2018;29:193-199.
PubMed Abstract available

RICORDEL C, Friboulet L, Facchinetti F, Soria JC, et al
Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
Ann Oncol. 2018;29.
PubMed Abstract available

December 2017

KORDBACHEH T, Honeychurch J, Blackhall F, Faivre-Finn C, et al
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms.
Ann Oncol. 2017 Dec 22. pii: 4772556. doi: 10.1093.
PubMed Abstract available

GUIHOT A, Marcelin AG, Massiani MA, Samri A, et al
Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.
Ann Oncol. 2017 Dec 1. pii: 4677259. doi: 10.1093.
PubMed

BI N, Liang J, Wang L
Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'.
Ann Oncol. 2017;28:3101-3103.
PubMed

November 2017

YOSHIDA H, Kim YH, Ozasa H, Nagai H, et al
Nivolumab in non-small cell lung cancer with EGFR mutation.
Ann Oncol. 2017 Nov 17. doi: 10.1093.
PubMed

EK L, Gezelius E, Bergman B, Bendahl PO, et al
Randomized Phase III Trial of Low Molecular Weight Heparin Enoxaparin in Addition to Standard Treatment in Small Cell Lung Cancer: the RASTEN Trial.
Ann Oncol. 2017 Nov 2. doi: 10.1093.
PubMed Abstract available

HAYASHI H, Mitsudomi T
S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West?
Ann Oncol. 2017;28:2627-2629.
PubMed

October 2017

OTSUBO K, Seki N, Nakanishi Y, Okamoto I, et al
Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small cell lung cancer.
Ann Oncol. 2017 Oct 23. doi: 10.1093.
PubMed

ULAHANNAN D, Khalifa J, Faivre-Finn C, Lee SM, et al
Emerging treatment paradigms in brain metastasis in non-small cell lung cancer: an overview of the current landscape and challenges ahead.
Ann Oncol. 2017 Oct 17. doi: 10.1093.
PubMed Abstract available

SORIA JC, Fulop A, Maciel C, Fischer JR, et al
SELECT-2: a Phase II, double-blind, randomised, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment for patients with advanced or metastatic non-small cell lung cancer.
Ann Oncol. 2017 Oct 3. doi: 10.1093.
PubMed Abstract available

MARTINEZ-MARTI A, Felip E, Matito J, Mereu E, et al
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Ann Oncol. 2017;28:2451-2457.
PubMed Abstract available

CALVO E, Moreno V, Flynn M, Holgado E, et al
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
Ann Oncol. 2017;28:2559-2566.
PubMed Abstract available

September 2017

NOKIHARA H, Lu S, Mok TSK, Nakagawa K, et al
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
Ann Oncol. 2017 Sep 29. doi: 10.1093.
PubMed Abstract available

WEBER S, Wolkewitz M, Schumacher M
Analyzing the impact of Depth of Response on Survival in patients with metastatic non-small cell lung cancer.
Ann Oncol. 2017 Sep 26. doi: 10.1093.
PubMed

ARGIRIS A, Lee JW, Stevenson J, Sulecki MG, et al
Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3508).
Ann Oncol. 2017 Sep 18. doi: 10.1093.
PubMed Abstract available

BUTTERBAUGH ST, Patel R, Romond EH, Mathew A, et al
Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: To continue or not to continue.
Ann Oncol. 2017 Sep 18. doi: 10.1093.
PubMed

KATAKAMI N, Felip E, Spigel DR, Kim JH, et al
A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
Ann Oncol. 2017;28:2241-2247.
PubMed Abstract available

ITO M, Fujiwara S, Fujimoto D, Mori R, et al
Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient.
Ann Oncol. 2017;28:2318-2319.
PubMed

MANAPOV F, Eze C
Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest.
Ann Oncol. 2017;28:2319-2320.
PubMed

August 2017

SAAD ED, Buyse M
Editorial on "Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small cell lung cancer treated with a targeted therapy or immunotherapy".
Ann Oncol. 2017 Aug 23. doi: 10.1093.
PubMed

KOLLER M, Hjermstad MJ, Tomaszewski KA, Tomaszewska IM, et al
An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients.
Ann Oncol. 2017 Aug 22. doi: 10.1093.
PubMed Abstract available

MAENO K, Fukuda S, Oguri T, Niimi A, et al
Nivolumab-induced asthma in a patient with non-small cell lung cancer.
Ann Oncol. 2017 Aug 22. doi: 10.1093.
PubMed

MCCOACH CE, Blumenthal GM, Zhang L, Myers A, et al
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small cell lung cancer treated with a targeted therapy or immunotherapy.
Ann Oncol. 2017 Aug 2. doi: 10.1093.
PubMed Abstract available

CURIONI-FONTECEDRO A, Ickenberg C, Franzen D, Rogler G, et al
Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab.
Ann Oncol. 2017;28:2040-2041.
PubMed

July 2017

LEDUC C, Merlio JP, Besse B, Blons H, et al
Clinical and molecular characteristics of non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
Ann Oncol. 2017 Jul 28. doi: 10.1093.
PubMed Abstract available

HENTRICH M, Schipek-Voigt K, Jager H, Schulz S, et al
Nivolumab in HIV-related non-small-cell lung cancer.
Ann Oncol. 2017 Jul 6. doi: 10.1093.
PubMed

Appendix 8: Metastatic non-small-cell lung cancer (2): eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
Ann Oncol. 2017;28.
PubMed

Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
Ann Oncol. 2017;28.
PubMed

POSTMUS PE, Kerr KM, Oudkerk M, Senan S, et al
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2017;28.
PubMed

BOLAND JM, Mansfield AS, Roden AC
Pulmonary sarcomatoid carcinoma-a new hope.
Ann Oncol. 2017;28:1417-1418.
PubMed

PECUCHET N, Vieira T, Rabbe N, Antoine M, et al
Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities.
Ann Oncol. 2017;28:1597-1604.
PubMed Abstract available

LESAFFRE E, Edelman MJ, Hanna NH, Park K, et al
Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.
Ann Oncol. 2017;28:1419-1426.
PubMed Abstract available

June 2017

TOMITA Y, Sueta D, Kakiuchi Y, Saeki S, et al
Acute Coronary Syndrome as a Possible Immune-Related Adverse Event in a Lung Cancer Patient Achieving a Complete Response to Anti-PD-1 Immune Checkpoint Antibody.
Ann Oncol. 2017 Jun 23. doi: 10.1093.
PubMed

LINDSAY CR, Faugeroux V, Michiels S, Pailler E, et al
A Prospective Examination of Circulating Tumor Cell Profiles in Non-Small Cell Lung Cancer Molecular Subgroups.
Ann Oncol. 2017 Jun 19. doi: 10.1093.
PubMed Abstract available

DEVARAKONDA S, Govindan R
TRAC(ERx)-ing Lung Cancer Evolution.
Ann Oncol. 2017 Jun 19. doi: 10.1093.
PubMed

SANMAMED MF, Perez-Gracia JL, Schalper KA, Fusco JP, et al
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients.
Ann Oncol. 2017 Jun 8. doi: 10.1093.
PubMed Abstract available

DURUISSEAUX M, Mc Leer-Florin A, Moro-Sibilot D, Cadranel J, et al
Are ALK rearrangement variants promising predictive biomarker of ALK tyrosine kinase inhibitors efficacy?
Ann Oncol. 2017;28:1401.
PubMed

KIM HR, Kang HN, Shim HS, Kim EY, et al
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
Ann Oncol. 2017;28:1250-1259.
PubMed Abstract available

May 2017

CHRISTOPOULOS P, Engel-Riedel W, Grohe C, Kropf-Sanchen C, et al
Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
Ann Oncol. 2017 May 23. doi: 10.1093.
PubMed Abstract available

CURROW D, Temel JS, Abernethy A, Milanowski J, et al
ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia.
Ann Oncol. 2017 May 4. doi: 10.1093.
PubMed Abstract available

GUBERINA M, Eberhardt W, Stuschke M, Gauler T, et al
Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial.
Ann Oncol. 2017;28:1084-1089.
PubMed Abstract available

ZHANG L, Ye Y, Tu H, Hildebrandt MA, et al
MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk.
Ann Oncol. 2017;28:1124-1129.
PubMed Abstract available

BESSE B, Mazieres J, Ribassin-Majed L, Barlesi F, et al
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
Ann Oncol. 2017;28:1078-1083.
PubMed Abstract available

April 2017

DHILLON HM, Bell ML, van der Ploeg HP, Turner JD, et al
Impact of Physical Activity on Fatigue and Quality of Life in People with Advanced Lung Cancer: a Randomised Controlled Trial.
Ann Oncol. 2017 Apr 28. doi: 10.1093.
PubMed Abstract available

HARATANI K, Hayashi H, Tanaka T, Kaneda H, et al
Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status after Disease Progression During EGFR-TKI Treatment.
Ann Oncol. 2017 Apr 12. doi: 10.1093.
PubMed Abstract available

SEO S, Woo CG, Lee DH, Choi J, et al
The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small cell lung cancer.
Ann Oncol. 2017 Apr 12. doi: 10.1093.
PubMed

FERRONIKA P, van den Bos H, Taudt A, Spierings DCJ, et al
Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small cell lung cancer patient.
Ann Oncol. 2017 Apr 11. doi: 10.1093.
PubMed

ZHANG Y, Zhang L, Li R, Chang DW, et al
Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility.
Ann Oncol. 2017 Apr 5. doi: 10.1093.
PubMed Abstract available

REMON J, Caramella C, Jovelet C, Lacroix L, et al
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
Ann Oncol. 2017;28:784-790.
PubMed Abstract available

March 2017

KATAOKA Y, Ebi N, Fujimoto D, Hara S, et al
Prior radiotherapy does not predict nivolumab response in non-small cell lung cancer: a retrospective cohort study.
Ann Oncol. 2017 Mar 20. doi: 10.1093.
PubMed

KIM ST, Kim SY, Klempner SJ, Yoon J, et al
Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Ann Oncol. 2017;28:547-554.
PubMed Abstract available

CHANDRANI P, Prabhash K, Prasad R, Sethunath V, et al
Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
Ann Oncol. 2017;28:597-603.
PubMed Abstract available

February 2017

ZOU T, Awad MM
More valuable than platinum: first-line pembrolizumab in advanced stage non-small cell lung cancer.
Ann Oncol. 2017 Feb 27. doi: 10.1093.
PubMed

GUBERINA M, Eberhardt W, Stuschke M, Gauler T, et al
Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomised trial.
Ann Oncol. 2017 Feb 21. doi: 10.1093.
PubMed Abstract available

MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
European cancer mortality predictions for the year 2017, with focus on lung cancer.
Ann Oncol. 2017 Feb 21. doi: 10.1093.
PubMed Abstract available

PAZ-ARES L, Tan EH, O'Byrne K, Zhang L, et al
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Ann Oncol. 2017;28:270-277.
PubMed Abstract available

YOSHIOKA H, Katakami N, Okamoto H, Iwamoto Y, et al
A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.
Ann Oncol. 2017;28:285-291.
PubMed Abstract available

REMON J, Soria JC
Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.
Ann Oncol. 2017;28:196-198.
PubMed

YANG TO, Cairns BJ, Reeves GK, Green J, et al
Cancer risk among 21st century blood transfusion recipients.
Ann Oncol. 2017;28:393-399.
PubMed Abstract available

YU HA, Sima C, Feldman D, Liu LL, et al
Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.
Ann Oncol. 2017;28:278-284.
PubMed Abstract available

January 2017

KADARA H, Choi M, Zhang J, Parra ER, et al
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Ann Oncol. 2017;28:75-82.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: